Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer
in men predicted to have specific genetic mutations (a high neoantigen load). Immunotherapy
with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. PARPs are
proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP
from working, so tumor cells can't repair themselves, and they may stop growing. Giving
durvalumab and olaparib may kill more tumor cells in patients with prostate cancer predicted
to have a high neoantigen load.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
AstraZeneca National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Olaparib Poly(ADP-ribose) Polymerase Inhibitors